Protara Therapeutics Inc. (TARA)
NASDAQ: TARA
· Real-Time Price · USD
3.13
-0.04 (-1.26%)
At close: May 23, 2025, 3:59 PM
3.22
2.88%
After-hours: May 23, 2025, 07:57 PM EDT
Company Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases.
The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.
It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.
The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020.
Protara Therapeutics, Inc. is headquartered in New York, New York.
Protara Therapeutics Inc.
| Country | United States |
| IPO Date | Oct 22, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Jesse Shefferman |
Contact Details
Address: 345 Park Avenue South New York, New York United States | |
| Website | https://www.protaratx.com |
Stock Details
| Ticker Symbol | TARA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001359931 |
| CUSIP Number | 74365U107 |
| ISIN Number | US74365U1079 |
| Employer ID | 20-4580525 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jesse Shefferman | Co-founder, Chief Executive Officer, President & Director |
| Dr. Shane Williams Ph.D. | Chief People Officer |
| Patrick Fabbio M.B.A. | Chief Financial Officer |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder & Chief Scientific Operations Officer |
| Dr. Leonardo Viana Nicacio M.D. | Chief Medical Officer |
| Hannah Fry | Vice President, Principal Accounting Officer & Controller |
| Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs |
| Mary J. Grendell J.D. | General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 19, 2025 | 4/A | [Amend] Filing |
| May 16, 2025 | 4 | Filing |
| May 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 08, 2025 | 10-Q | Quarterly Report |
| May 08, 2025 | 8-K | Current Report |
| Apr 28, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 28, 2025 | 424B7 | Filing |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 25, 2025 | DEFA14A | Filing |